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After 
 
 
 
8,000 infections and 
 
 
 
700 deaths worldwide, the pathogenesis of the new 
infectious disease, severe acute respiratory syndrome (SARS), remains poorly understood. 
We investigated 18 autopsies of patients who had suspected SARS; 8 cases were confirmed 
as SARS. We evaluated white blood cells from 22 confirmed SARS patients at various stages 
of the disease. T lymphocyte counts in 65 confirmed and 35 misdiagnosed SARS cases also 
were analyzed retrospectively. SARS viral particles and genomic sequence were detected in a 
large number of circulating lymphocytes, monocytes, and lymphoid tissues, as well as in the 
epithelial cells of the respiratory tract, the mucosa of the intestine, the epithelium of the 
renal distal tubules, the neurons of the brain, and macrophages in different organs. SARS 
virus seemed to be capable of infecting multiple cell types in several organs; immune cells 
and pulmonary epithelium were identified as the main sites of injury. A comprehensive 
theory of pathogenesis is proposed for SARS with immune and lung damage as key features.
 
The target organ of severe acute respiratory
syndrome (SARS) is widely believed to be
the lungs, hence the names “severe acute
respiratory syndrome” and “SARS atypical
pneumonia” (1, 2). However, patients often
have evidence of other organ dysfunction, in-
cluding gastrointestinal symptoms (3), abnormal
liver function (4, 5), splenic atrophy, and
lymphadenopathy (6). This may reflect wide-
spread immunopathology or the presence of
extrapulmonary SARS-coronavirus (CoV) dis-
semination and replication, as has been ob-
served in other species infected with animal
coronavirus (7). Recent reports of multiple or-
gan infection by the virus were based mostly
on partial autopsies (8). A comprehensive the-
ory of pathogenesis for this newly emerged in-
fectious disease is lacking.
We report here on our postmortem study
of 18 patients who had suspected SARS who
died 14–62 d after the onset of symptoms. In
addition, blood samples were examined from
22 cases of confirmed SARS, 3–29 d after the
onset of symptoms. We also investigated the
immune cell lesion in 100 patients who had
suspected SARS who were admitted to our
hospitals; 35 were found retrospectively to
have been misdiagnosed. We set out to verify a
hypothesis of immune cell injury–based damage
for the pathogenesis of SARS. Analysis of our
newly obtained histologic and molecular data,
and clinical information revealed a more com-
plete picture of the infection.
 
RESULTS
 
8 of the 18 suspected SARS victims were con-
firmed as having SARS by demonstration of
the pathogen with real-time RT-PCR, in situ
hybridization, and electron microscopy (EM).
All cases had similar pathologic changes in
their lungs, immune system, and other or-
gans. Differences in the severity of pathologic
changes were noted among SARS cases,
which varied with the duration of the disease
before death. The examination of the blood
samples from patients who had early-stage
SARS provided insights into the pathologic
changes at the early phase of the disease. Dis-
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tinct differences in lymphocyte counts between confirmed
and misdiagnosed cases also were demonstrated. These are
reported in the following text.
 
Respiratory tract
 
The affected lungs showed severe consolidation with tissue
consistency approximating that of the liver (Fig. 1 A). The
SARS lungs were, on average, three to four times heavier
than normal lungs. Conventional light microscopy (LM)
demonstrated widespread damage of the lung parenchyma,
with extensive fibrin exudate, edema, interstitial thicken-
ing, and extensive hyaline membrane formation (Fig. 1 B).
There was extensive alveolar collapse, and the remaining
alveoli were filled with fluid and desquamated alveolar and
bronchial epithelial cells. Alveolar epithelial hyperplasia
was evident. Large syncytial cells with multiple nuclei
were present. Small vessel vasculitis was seen. However,
cellular infiltrate was rare and conspicuously absent in
most cases, and lymphocytic infiltration was sparse. Over-
all, the diffuse alveolar damage resembled that seen in adult
respiratory distress syndrome, but with a paucity of inflam-
matory infiltrate.
In situ hybridization demonstrated SARS viral se-
quences in the cytoplasm of a large number of intact and
degenerating epithelial cells of the lungs as well as in the
scanty infiltrating lymphocytes and clustered macrophages
(Fig. 1, C and D). Pulmonary epithelial cells were identified
with immunostaining using antibodies to AE1 and AE3.
The giant syncytial cells were particularly rich in hybridiza-
tion signals. Monocytes and lymphocytes in blood vessels of
the lungs also were positive for in situ hybridization (Fig. 1
E). Negative control for in situ hybridization of SARS ge-
nomic sequence of the lung showed no positive signal when
an unrelated probe was used (Fig. 1 F). EM demonstrated
SARS-like viral particles in the cytoplasm of the epithelial
cells (Fig. 1, H and I). In situ hybridization with specific
probes, and colloid gold-labeled secondary antibodies de-
tected specific positive signals in the cytoplasm of epithelial
cell types I and II at the EM level (Fig. 1 G). Double label-
ing of SARS-infected cells with in situ hybridization and
cytokeratin immunolabeling revealed that pulmonary epi-
thelial cells were infected by SARS virus. The proliferative
cells in the lungs were mainly type II cells as evidenced by
their LM morphology.
SARS viral sequences also were detected in the epithelial
cells of the trachea, bronchi, and bronchioles by in situ hy-
bridization (Fig. 1 J). More than 50% of ciliated epithelial
cells in the trachea displayed positive cytoplasmic in situ hy-
bridization; no positive signal was detected in the negative
control when an unrelated probe was used (Fig.1 K).
Figure 1. SARS pathology in the respiratory tract. (A) Lung of a 
SARS victim. The cut surface showed severe edema, consolidation, and 
hemorrhage. (B) LM of hematoxylin and eosin preparation of a SARS 
lung. The interstitial tissue was thickened with fibrin exudation and or-
ganization. Many alveoli were collapsed, filled with fluid, and exhibited 
hyaline membranes. Cellular infiltration was not obvious. Bar, 50  m. 
(C) In situ hybridization of SARS genomic sequence of the lung from a 
SARS victim who died 62 d after the onset of high fever detected a large 
number of pulmonary epithelial cells (small arrows) that contained the 
virus. Multinuclear giant syncytial cells found in the alveoli contained a 
large amount of SARS viral sequences (large arrows). Bar, 80  m. (D) In 
situ hybridization of SARS genomic sequence of the lung from a SARS 
victim who died 35 d after the initial symptoms showed macrophages 
(large arrows) in an alveolus, and many pulmonary epithelial cells (small 
arrows) contained the virus. Bar, 100  m. (E) Blood vessel in SARS lung—
double labeling, immunohistochemistry of CD68—brown (thin arrows). In 
situ hybridization of SARS viral sequence—black (thick arrows). A mixed 
color (arrowheads) indicates that monocyte was infected by SARS virus. 
The black color also may overshadow the brown color when both are 
present in the same blood cells and the in situ hybridization signal is very 
strong. Bar, 100  m. (F) Negative control for in situ hybridization of 
SARS genomic sequence of the lung. No positive signal was detected. 
Bar, 100  m. (G) EM in situ hybridization with colloidal gold labeling (10 
nm gold; arrows) of viral sequence demonstrated that type II epithelial 
cells of the lung contained the virus. Bar, 0.2  m. (H) EM image of a 
portion of an epithelial cell in the lung of a patient who had SARS. The 
region indicated by the arrow is enlarged in I. Bar, 2  m. (I) Enlargement 
of the region in H. A large number of SARS virus–like particles (arrows) 
was observed. Bar, 0.5  m. (J) In situ hybridization of SARS viral sequence 
demonstrated that most of the ciliated epithelial cells (arrows) of the 
trachea from a patient who had SARS were infected by the virus. Bar, 
50  m. (K) Negative control for in situ hybridization of SARS genomic 
sequence of the trachea from a patient who had SARS. No positive signal 
was detected. Bar, 50  m.
 
Table I.
 
Percent of granulocytes, monocytes, and lymphocytes 
in SARS and control patients
 
No. of 
cases
No. of 
granulocytes
No. of 
monocytes
No. of 
lymphocytes
 
Normal 4 66.5 
 
 
 
 4.8 8.8 
 
 
 
 1.4 24.8 
 
 
 
 2.3
SARS 6 83.2 
 
 
 
 6.9
 
a
 
6.2 
 
 
 
 0.9
 
b
 
10.7 
 
 
 
 1.0
 
a
 
a
 
P 
 
 
 
 0.01 compared with normal.
 
b
 
P 
 
 
 
 0.05 compared with normal.  
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Immune cells
 
Among the 22 SARS blood samples that were obtained from
the early stages of the disease, EM detected SARS-like viral
particles in monocytes and lymphocytes of six patients. These
round viral particles, with diameters of 80–120 nm, were lo-
cated in the cytoplasm. The particles had double membranes
and pale cores with short processes that projected outward.
The percentage of total circulating lymphocytes was de-
creased (Table I). The percentages of different cell types that
harbored SARS-like viral particles are shown in Table II.
Positive samples included those taken within 10 d of the on-
set of fever, and in one instance as early as 3 d. Most of the
infected cells were T cells. Some B cells and NK cells also
were infected by the virus. By EM, the viral particles tended
to form clusters and were located within or near the endo-
plasmic reticulum. T lymphocytes were identified by their
unique morphology with a size of 
 
 
 
8–15 
 
 
 
m in diameter;
round shape with irregular cell membranes and small villous
processes; large rounded, but sometimes, irregular nucleus;
and small quantities of cytoplasm devoid of lysosomes. Label-
ing of these cells with antibody to CD3 and pre-embedding
immunoperoxidase labeling for EM further confirmed the
nature of these cells. The macrophages appeared to be acti-
vated as they became slightly larger. The nature of these cells
was confirmed with immunohistochemistry of CD68.
In the autopsy samples, in situ hybridization and EM
demonstrated virus-infected immune cells in the circulating
blood, spleen, lymph nodes, and lymphoid tissue of various
organs. A large proportion of lymphocytes in the circulation
and lymphoid organs contained the virus (Fig. 2, A and B).
The spleen and lymph nodes were atrophic (Fig. 2 L).
The average weight of the spleen was 62% of that of controls
and unconfirmed cases. LM with hematoxylin and eosin
staining revealed a notable decrease of lymphocytes in these
organs (Fig. 2 C). Immunolabeling with seven markers was
 
Table II.
 
Percent of white blood cells containing coronavirus-
like particles in SARS patients (
 
n
 
 
 
 
 
 6)
 
Total cells Cells with virus particles Positive cells
 
mean 
 
 
 
 SEM mean 
 
 
 
 SEM %
 
Granulocytes 83.2 
 
 
 
 6.9 2.5 
 
 
 
 0.4 3.0
Monocytes 6.2 
 
 
 
 0.9 1.8 
 
 
 
 0.4 29.7
Lymphocytes 10.7 
 
 
 
 1.0 5.5 
 
 
 
 0.7 51.5
 
Figure 2. SARS pathology in the immune system. 
 
(A) EM image of a 
circulating T lymphocyte in a patient who had SARS 6 d after onset of 
fever. Bar, 2 
 
 
 
m. Inset: A higher power view of the region in panel A. A 
group of SARS coronavirus-like particles was located in the cytoplasm. 
Bar, 0.2 
 
 
 
m.
 
 
 
(B) EM image of the cytoplasm of a lymphocyte showing 
three coronavirus-like particles (arrows) in the cytoplasm. The lower two 
are located near the cell membrane. The one on the lower left seems to 
have just trespassed the membrane and entered the lymphocyte. Bar, 0.5 
 
 
 
m. 
Inset: A higher power EM image of the membrane region of a peripheral 
lymphocyte. A coronavirus-like particle (arrow) is shown entering the 
target cell, and the cell membrane still fused with the viral envelope. 
E, extracellular space. Bar, 0.1 
 
 
 
m. Similar SARS coronavirus-like particles 
were not detected in the lymphocytes of non-SARS patient (not depicted).
 
 
 
(C) LM hematoxylin and eosin staining of the spleen from a patient who 
had SARS showing depletion of periarterial lymphatic sheath and dilation 
of splenic sinusoid. No splenic corpuscle was preserved. Bar, 200 
 
 
 
m. 
(D) LM immunohistochemistry staining of the spleen from a misdiagnosed 
patient shows the normal distribution and size of CD68
 
 
 
 macrophages. 
Bar, 20 
 
 
 
m. (E) LM immunohistochemistry staining of the spleen from a 
patient who had confirmed SARS shows that CD68
 
 
 
 macrophages are 
larger than those in the misdiagnosed case. Bar, 20 
 
 
 
m. (F) Negative con-
trol for immunohistochemistry staining of the spleen from a patient who 
had confirmed SARS in which PBS was substituted for the anti-CD68 anti-
body. No positive signal was detected. Bar, 20 
 
 
 
m. (G) In situ hybridization 
detected SARS genomic sequence positive lymphocytes (arrows) in the 
spleen from a SARS autopsy. Bar, 70 
 
 
 
m. (H) In situ hybridization detected 
SARS genomic sequence positive lymphocytes (arrows) in a lymph node 
from the hilus of the lung of a SARS autopsy. Bar, 70 
 
 
 
m. (I) Negative 
control for in situ hybridization of SARS genomic sequence of the lym-
phocytes in the spleen from a SARS autopsy, in which an unrelated probe 
was used. No positive signal was detected. Bar, 100 
 
 
 
m. (J) In situ hybrid-
ization detected SARS genomic sequence positive lymphocytes in the 
vessel of thyroid gland from a SARS autopsy. Bar, 70 
 
 
 
m. (K) Negative 
control for in situ hybridization of SARS genomic sequence, in which the 
specific probe was substituted by an unrelated probe, of the lymphocytes 
in thyroid gland of a SARS autopsy. No positive signal was detected. Bar, 
70 
 
 
 
m. (L) Spleen of a 51-yr-old male patient who had SARS. The spleen 
was atrophic with a wrinkled capsule. The texture was very soft. LM revealed 
marked depletion of the lymphoid population in the spleen. (M) In situ 
hybridization detected SARS genomic sequence positive lymphocytes 
(arrows) in a lymph node dissected from the mesentery of a SARS autopsy. 
Bar, 50 
 
 
 
m. 
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undertaken to identify seven cell types (Table III). All im-
mune cell types, including dendritic cells, were decreased sig-
nificantly (P 
 
 
 
 0.01), and CD68 positive macrophages, which
were decreased in number, were noticeably (P 
 
 
 
 0.01) in-
creased in size and gave the impression of macrophage activa-
tion (Fig. 2, D and E). In the negative control for immuno-
histochemistry of spleens from confirmed SARS patients in
which PBS was substituted for the anti-CD68 antibody, no
positive signal was detected (Fig. 2 F). In situ hybridization
identified the SARS viral sequence in the enlarged macro-
phages and in the isolated and sometimes clustered T lympho-
cytes, which were distributed mostly at the periphery of the
germinal centers of the splenic white pulp, lymph nodes, and
peripheral blood (Fig. 1 E; Fig. 2 G, H, J, and M).
The lymphoid component of the intestine showed wide-
spread degenerative changes. The lymphoid follicles (Peyer’s
patches) showed markedly decreased lymphocytes (Fig. 3 A),
and in severe cases only the depleted stromal framework of
the structure remained. EM detected viral particles in the
submucosa of the gut (Fig. 3, B and C) and within the resid-
ual lymphocytes. In situ hybridization demonstrated the
presence of SARS positivity in the lymphocytes of the mu-
cosa and the submucosa (Fig. 3 D). Positive signal was not
found in the negative control, in which no specific probe
were used, or in the non-SARS cases (Fig. 3, E and F).
 
Digestive tract
 
In all of the confirmed SARS cases, the digestive tract displayed
mild inflammatory changes. The most obvious lesions in the di-
gestive tract were the depletions of the submucosa lymphoid
tissues described above (Fig. 3 A). In addition, the epithelial
cells of mucosa of the small and large intestines were found to
be infected by the virus by in situ hybridization and EM (Fig. 3
G). Similar positive cells were not found in the stomach or the
esophagus. Detailed descriptions of gastrointestinal involvement
in SARS are reported separately (9). Such positive reaction was
not seen in the negative controls—in which no specific probe
was used—or in the non-SARS cases (Fig. 3, H and I).
 
Kidneys
 
The kidneys were focally hemorrhagic. In situ hybridization
localized viral sequences to the epithelial cells of the renal dis-
tal tubules (Fig. 3 J). Clusters of SARS viral particles also were
detected in the cytoplasm of the distal tubular epithelium by
EM (Fig. 3, M and N). The specificity of the above reactions
was established with the negative controls (Fig. 3, K and L).
 
Brain
 
SARS genome sequences were detected in the brain of all
SARS autopsies with LM, EM, and with real-time RT-PCR.
The signals were confined to the cytoplasm of numerous neu-
rons in the hypothalamus and cortex (Fig. 3 O). Edema and
scattered red degeneration of the neurons were present in the
brains of six of the eight confirmed cases of SARS. SARS viral
sequences and pathologic changes were not present in the
brains of unconfirmed cases or control cases (Fig. 3, P and Q).
 
Other organs
 
In five out of the eight confirmed cases, hepatocytes in the
centrilobular zone showed apparent degenerative changes.
The testes of the seven male patients displayed focal atrophy.
However, SARS viral sequences and viral particles were not
identified in the parenchymal cells by in situ hybridization or
EM in these organs. No obvious pathologic change was ob-
served in the heart, the pancreas, the adrenal gland, the thy-
roid gland, or the skeletal muscle, although SARS-harboring
lymphocytes and monocytes were found in some of these
organs, mostly within vessels. Tissue samples from the
mouth, the nasal mucosa, and the bone marrow were not
available for examination.
 
T lymphocyte counts
 
Retrospective analyses revealed significant differences in T
lymphocyte subtypes in blood samples that were collected at
different time points from the onset of the disease in con-
firmed SARS patients versus misdiagnosed cases (P 
 
 
 
 0.05;
Fig. 4). T lymphocytes (CD3
 
 
 
, CD4
 
 
 
, and CD8
 
 
 
 cells)
were decreased at the onset of symptoms; this decrease per-
sisted until the recovery phase. When glucocorticoids were
administered, the lymphocytes were decreased further in
both groups of patients; however, the difference in lympho-
cyte counts between the SARS and non-SARS cases per-
sisted. The differences in other blood cell types in these pa-
tients were not significant and are not shown.
 
Table III.
 
Antibodies for IHC
 
Primary
antibody Supplied by Cell marker Dilution Temperature Incubation period
 
CD3 Novocastra Laboratories Ltd. T cell 1:100 20
 
 
 
C 120 min
CD4 Novocastra Laboratories Ltd. helper T cell 1:25 4
 
 
 
C 24 hr
CD8 Novocastra Laboratories Ltd. cytotoxic T cell 1:50 20
 
 
 
C 90 min
CD20 Novocastra Laboratories Ltd. B cell 1:100 20
 
 
 
C 90 min
 
CD56
 
Zymed Laboratories NK cell 1:50 20
 
 
 
C 90 min
S100 Zymed Laboratories dendritic cell 1:50 20
 
 C 90 min
CD68 Zymed Laboratories macrophage, monocyte 1:100 20 C 90 min
AE1 and AE3 DakoCytomation epithelial cell 1:100 20 C 90 minJEM VOL. 202, August 1, 2005 419
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Comparison of SARS and non-SARS cases
All confirmed SARS cases had similar pathologic changes in
the lungs and lymphoid organs that differed only in severity.
The severity of damage to the immune system and the extent
of pulmonary damage and fibrosis corresponded with the du-
ration of the disease, as counted from the onset of symptoms.
In contrast, the suspected, but unconfirmed, cases demon-
strated a wide range of pathology that varied with the etiol-
ogy of each case. In three cases, the pathologic changes in the
lungs were similar to those seen in the confirmed cases of
SARS. However, the edema, consolidation, hyaline mem-
brane formation, and fibrosis were less prominent, and there
was no damage to the pulmonary epithelial cells. Multiple or-
gan infection was a characteristic feature for confirmed cases
of SARS, but not for the other patients. The damage to the
immune system was found only in the patients who had
SARS, but not in patients who had similar symptoms but did
not harbor the virus. Neuronal changes with demonstrated
SARS virus infection were unique to patients who had
SARS, and were not found in the misdiagnosed cases. All
controls used in SARS assays were negative, and thereby es-
tablished the specificity of in situ hybridization and immuno-
histochemistry procedures. Additional controls, including
those for the double labeling, excluded the possibility of in-
terference between the in situ hybridization and the immu-
nohistochemical reactions when performed in combination.
DISCUSSION
In addition to confirming the previously reported pathologic
changes in SARS (6, 10–12), we have demonstrated wide-
spread dissemination of the SARS virus in the immune cells
of the blood, spleen, and lymph nodes, as well as in the epi-
thelial cells of the lungs, trachea, bronchi, distal renal tu-
bules, mucosa, and submucosa of the intestines, and neurons
of the brain. The presence and localization of the virus in
these target cells were confirmed by in situ hybridization,
EM, and real-time PCR.
It is evident that infection by the SARS virus is not con-
fined to the lungs, but also involves other parts of the respi-
ratory tract and other organ systems, most importantly im-
mune cells, particularly the T lymphocytes, monocytes, and
macrophages. The finding of early and consistent decreases
of T lymphocytes in 65 patients who had SARS, but not in
the 35 misdiagnosed patients, further suggests that lympho-
Figure 3. SARS pathology in the gut, kidney, and brain. (A) Depletion 
of mucosal lymphoid tissue of the small intestine of a patient who had 
SARS, showing decreased number of lymphocytes and depletion of germinal 
center. Bar, 200  m. (B) EM image of a portion of mucosal cell in the small 
intestine of a SARS autopsy. M, microvilli; N, nucleus. The area indicated 
by the white arrow is enlarged in C. Bar, 2  m. (C) Higher magnification of 
a SARS virus–containing vesicle (white arrow) in the same cell as shown in 
B. Bar, 0.2  m. (D) In situ hybridization detected SARS sequence positive 
signal (arrows) in the cytoplasm of lymphocytes in the submucosal lym-
phoid tissue. Bar, 30  m. (E) Negative control for in situ hybridization of 
SARS genomic sequence of the lymphocytes in the submucosal lymphoid 
tissue, in which an unrelated probe was used. No positive signal was de-
tected. Bar, 30  m. (F) In situ hybridization of SARS genomic sequence of 
lymphocytes in the submucosal lymphoid tissue of a patient who did not 
have SARS. No positive signal was detected. Bar, 30  m. (G) In situ hybrid-
ization showing SARS-CoV positive signals (arrows) in the cytoplasm of a 
few mucosal epithelial cells in the small intestine of a patient who had 
SARS. Bar, 100  m. (H) Negative control for in situ hybridization of SARS 
genomic sequence of mucosal epithelial cells in the small intestine of a 
patient who had SARS, in which an unrelated probe was used. No positive 
signal was detected. Bar, 100  m. (I) In situ hybridization of SARS genomic 
sequence of mucosal epithelial cells in the small intestine of a patient who 
did not have SARS. No positive signal was detected. Bar, 100  m. (J) In 
situ hybridization detected SARS genomic sequence in the tubular epithe-
lium (arrows) of the distal tubules of the kidney of a patient who had 
SARS. Bar, 70  m. (K) Negative control for in situ hybridization of SARS 
genomic sequence of the distal tubules of the kidney of a patient who had 
SARS, in which an unrelated probe was used. No positive signal was detected. 
Bar, 70  m. (L) In situ hybridization of SARS genomic sequence of the 
distal tubules of the kidney of a patient who did not have SARS. No posi-
tive signal was detected. Bar, 70  m. (M) EM image of the cytoplasm of a 
tubular epithelial cell in the kidney of a patient who had SARS. The area 
indicated by the arrow is enlarged in N. M, microvilli of a tubular epithelial 
cell. Bar, 1  m. (N) Enlargement of M. EM image of clusters of SARS virus–
like particles (arrows) were detected in the cell. Bar, 0.2  m. (O) In situ 
hybridization detected SARS genomic sequence in the cytoplasm of 
numerous neurons (arrows) in the brain of a patient who had SARS. Bar, 
100  m. (P) Negative control for in situ hybridization of SARS genomic 
sequence of neurons in the brain of a patient who had SARS in which the 
specific probe was not used. No positive signal was detected. Bar, 100  m. 
(Q) In situ hybridization of SARS genomic sequence of neurons in the 
brain of a patient who did not have SARS. No positive signal was detected. 
Bar, 100  m.PATHOGENESIS OF SARS | Gu et al. 420
cyte damage is the hallmark of SARS. Administration of glu-
cocorticoids contributed to a decrease in lymphocyte counts
in both groups of patients; however, the difference in counts
between the two groups persisted after glucocorticoid ther-
apy. It was reported that lymphopenia is one of the earliest
changes, and is a reliable prognostic predictor in SARS (13–
18). An extensive literature search has not revealed a report
of any other type of pneumonitis producing such severe
lymphopenia. As the only logical explanation for the early
and consistent lymphopenia that is demonstrated in patients
who have SARS, we suggest that lymphocytes—particularly
T lymphocytes—are infected and destroyed by the virus or
by other immune cells. Our study provides evidence of in-
fection and destruction of lymphocytes in the spleen, lymph
nodes, and lymphoid tissues of the gut. In these sites lym-
phocytes were reduced markedly, germinal centers were de-
pleted of lymphocytes, and in situ hybridization detected
SARS viral positivity in the residual immune cells in the
spleen and in circulation. This destruction of lymphocytes
would cause an acute immunodeficiency that would aggra-
vate the infection of the respiratory tract. The markedly
weakened immune system at the early and mid stages of the
disease is likely to be the reason for the acute nature and se-
verity of the respiratory syndrome in SARS viral infection.
Previously, there were reports that immune overreaction
played a role in the immune injury and pathogenesis of
SARS. However, there has been no concrete evidence to
support this notion. The data on lymphokine production in
SARS was not conclusive, and there was no report of a uni-
form and consistent increase of lymphocytes in those pa-
tients. The release of respiratory symptoms following steroid
treatment (19) could be attributed to the antiinflammatory
effect of the therapies, rather than immune suppression. Al-
though the role of immune hyperreaction, particularly in the
early phase of the diseases, could not be ruled out com-
pletely, the evidence that we obtained points more to a di-
rect immune injury as an important component in SARS
pathology and pathogenesis.
The pathologic changes in the digestive tract, and the di-
rect viral infection of mucosal epithelial cells and lymphoid
tissue in the mucosa and the submucosa of small and large
intestines, provide an explanation for the presence of the vi-
rus in the stool of patients who have SARS. Approximately
29% to 39.2% of patients who have SARS have diarrhea and
other digestive tract symptoms, and these symptoms oc-
curred  3.5–7.5 d after the onset of fever (15, 16). This pe-
riod likely is required for the virus to infect the immune cells
that circulate to attack and damage the gut. The continued
Figure 4. Lymphocyte subtypes in patients who had confirmed or 
misdiagnosed SARS. (A–C) The cell counts of CD3, CD4 and CD8, respec-
tively, at various time points after the onset of symptoms in patients who 
were not treated with glucocorticoids. The data indicate that the lympho-
cytes were decreased from the onset of the disease in patients who had 
SARS but not in patients who did not have SARS (confirmed SARS, n   15; 
misdiagnosed cases, n   15). D, E, and F show the cell counts of CD3, CD4, 
and CD8, respectively, in patients who had confirmed or misdiagnosed 
SARS at various time points after the onset of symptoms and who were 
treated with glucocorticoids (confirmed SARS, n   50; misdiagnosed 
cases, n   20). The lymphocytes were decreased in both groups. However, 
the differences in the two groups with regard to the extent of lymphocyte 
reduction remained the same. The results from the retrospective investi-
gation suggest that lymphopenia is a characteristic feature of SARS, and 
implicates an early and consistent destruction of lymphocytes.JEM VOL. 202, August 1, 2005 421
ARTICLE
shedding of the mucosal epithelial cells and the damaged
submucosal lymphocytes most likely are the source for the
virus in the stool. Because SARS-infected epithelial cells
were not found in the stomach and esophagus, it suggests
that the virus is not ingested but more likely is presented to
the gut by way of infected circulating immune cells. Reports
that demonstrated SARS in the small and large intestine sup-
port this hypothesis (20).
The selective infection of the distal renal tubules pro-
vides an explanation for the presence of the virus in the
urine, and perhaps for hematuria that may occur in patients
who have SARS (15, 16). The Vero E6 cells that were used
to identify and isolate the SARS coronavirus were derived
from the renal epithelial cells of the green monkey (21); this
suggests that kidney epithelial cells are inherently vulnerable
to SARS infection.
Infection of neurons seemed to occur in only selected areas
of the brain in all eight cases. The scattered red degeneration of
the neurons is a sign of neuronal hypoxia/ischemia. The obser-
vation of virus in neurons may provide an explanation for the
higher than usual incidence of neuronal and psychologic ab-
normalities that are seen in patients who have late-stage SARS
(22, 23). These neurologic symptoms previously were attrib-
uted to negative social pressure during the epidemic.
Postulated pathogenesis of SARS
Based on our findings, we propose the following pathogene-
sis mechanism of SARS. The SARS virus enters the body
through the respiratory tract and first infects the epithelial
cells of the trachea, bronchi, bronchioles, and lungs. The vi-
rus infects resident, infiltrating, and circulating immune cells.
The circulating immune cells carry the virus to other organs.
The virus infects and damages the immune cells of the spleen,
peripheral and central lymph nodes, and other lymphoid tis-
sues. The immune defense is weakened significantly, which
leads to rapid deterioration of the pneumonia. In the same
manner, the blood-borne SARS virus infects other organs. As
such, patients who have compromised immune function,
such as those who have chronic diseases and aged individuals,
suffer a more severe illness and have a much higher mortality
from SARS (15). The extent of immune cell damage, re-
flected by lymphocyte count, is a manifestation of the pa-
tient’s immune status and a predictor of outcome. The dam-
age to the immune system, more than damage to the lungs,
determines whether a patient recovers or dies from the infec-
tion. In a way, the name “sudden acute respiratory syn-
drome” is inappropriate because it diverts attention from the
primary pathologic changes that result from SARS virus in-
fection. It must be emphasized that immune damage most
likely is the primary determinant of clinical outcome.
This study unveils a hitherto unknown, but significant,
aspect of the pathogenesis of SARS. Our proposed mecha-
nism of infection and dissemination is capable of explaining
all of the clinical symptoms and laboratory findings that have
been reported for SARS. It provides a comprehensive theory
of pathogenesis for this new disease. In a way, SARS infec-
tion is similar to HIV infection that causes AIDS. Although
HIV attacks and destroys the target cells slowly, particularly
lymphocytes (24), SARS virus infects and destroys the im-
mune cells in a much faster and more devastating fashion.
Like many other infectious diseases, SARS infections show
differing degrees of severity in different individuals. Only the
most severe cases demonstrate the full range of pathologic
changes that was described above. Our findings suggest that
body fluid and fecal–respiratory tract transmission of the vi-
rus, although not reported, is possible because SARS viruses
or its sequences are detectable in the blood, intestines, stool,
and urine. A correct understanding of the pathogenesis is
crucial for developing animal models to test effective vac-
cines and to establish techniques for early diagnosis. Further
detailed studies of the immune damage will shed more light
on the true nature of the pathogenesis of SARS.
MATERALS AND METHODS
Autopsies were performed on 18 patients who were suspected to have died of
SARS infections; 15 died between June and August 2003 (7 confirmed as
SARS) and 3 died in April 2004 (one confirmed as SARS). The World
Health Organization’s diagnostic criteria for SARS (25) were used for clinical
diagnoses. These included SARS contact history, sudden onset of high fever,
respiratory symptoms, chest X-ray findings, and unresponsiveness to antibiotic
therapy. The clinical data on the 18 autopsied cases is presented in Table IV.
Retrospective analysis of suspected SARS cases provided a comparison be-
tween true and misdiagnosed SARS cases. The confirmation of SARS infec-
tion was made by real-time RT-PCR demonstration of the SARS virus–spe-
cific sequence in blood or tissue samples or SARS antibody positivity in the
sera of the patients. Cases were considered to represent a misdiagnosis when
repeated testing for SARS-specific antibody was negative (each case tested at
least twice, with tests 2 wk apart). The misdiagnosis rate in one of our hospi-
tals was  35%. These patients were admitted to the hospital because of
SARS-like symptoms, and in the initial period of the SARS epidemic, spe-
cific antibody tests and SARS genomic sequence detection were not available
for confirmation. Misdiagnosed cases were treated similarly to confirmed
cases of SARS. Autopsy tissue samples from 6 age-matched and otherwise
healthy subjects who died of head trauma served as controls.
Procedures for histopathologic investigation of the autopsies for LM and
EM were those performed routinely in laboratories as described previously
(26, 27). The technique of in situ hybridization was based on Zhang et al.
(28). In brief, a sequence of 154 bp was amplified by polymerase chain reac-
tion from the SARS coronavirus genome sequence. These sequence data are
available from GenBank/EMBL/DDBJ under accession no. AY274119. The
RNA probe was prepared by in vitro transcription in the presence of digox-
igenin-UTP. The in situ hybridization reaction was performed on formalin-
fixed and paraffin-embedded tissue sections with the SARS probe at 50  g/
ml. The hybridization cocktail was incubated at 55 C for 16 h. The alkaline
phosphatase-labeled antidigoxigenin antibody (1:500) was incubated for 60
min, and colorization was achieved with nitroblue tetrazolium/5-bromo-4-
chloro-3-indolyl phosphate and counterstained with methyl-green. Immu-
noelectron microscopy was based on the technique of Goldsmith et al. (29).
The EM in situ hybridization technique was based on Vandell et al. (26). In
brief, the in situ hybridization reaction was performed on the tissue grids in a
procedure similar to that for the LM. The labeled probe was detected with
colloidal gold (10 nm)–labeled antibody to digoxigenin. Immunohistochem-
istry was performed using a range of monoclonal antibodies to identify the
different cell types that were infected or affected by the virus (Table I). Im-
munohistochemistry was performed as described by Lin et al. (30), and anti-
gen retrieval technique was performed as described previously (31, 32). Real
time RT-PCR was performed with the technique of Wu et al. (33). In brief,PATHOGENESIS OF SARS | Gu et al. 422
total RNA was extracted from clinical samples using Trizol reagents accord-
ing to the manufacturer’s instructions. 1  g of total RNA was transcribed
into cDNA with the superscript first-strand cDNA synthesis system. Taqman
real-time quantitative PCR was conducted according to the manufacturer’s
instructions (Applied Biosystems). Three pairs of primers were designed and
constructed (Genbank G130027616 [15121–15661]). The designs of the
primers and the probes that were used for real-time PCR and in situ hybrid-
ization were those described previously (33). They were 5 -GCGCAAG-
TATTAAGTGAGATG-3  and 5 -GAAGTGCATTTACATTGGCTA-3 
as the innermost pair; 5 -ACACTTGCTGTAACTTATCAC-3  and 5 -
TCATAGAGCCTGTGTGTGAGG-3  as the outer pair; and 5 -CTAA-
CATGCTTAGGATAATGG-3  and 5 -CAGGTAAGCGTAACTTAT-
CAC-3  as the outermost pair. The molecular beacon technique was used
(33). The sensitivity and specificity of this standardized real-time RT-PCR
assay for the detection of SARS-CoV in postmortem lung tissues were estab-
lished previously (34).
To identify the cell types that were infected by the virus, double label-
ing was performed by combining in situ hybridization for SARS viral geno-
mic sequences and immunohistochemistry for one of the cell-associated
markers. The in situ hybridization signal was visualized with alkaline phos-
phatase, which results in a dark blue color, whereas positive immunostain-
ing signal was visualized with diamenobenzodin, which gives a reddish-
brown color. When the two signals are present in the same cell, the staining
changes to a purplish color, which is easily distinguishable from either of the
primary colors. In addition, in situ hybridization and immunohistochemis-
try were performed separately on consecutive sections to analyze the rela-
tionship between in situ hybridization signals and immunostaining signals to
ascertain the cell types that were infected by the virus. Seven cell marker
antigens were examined to identify epithelial cells, macrophages, T cells, B
cells, and splenic dendritic cells. The specificities and the sources of these
antibodies are shown in Table III.
Controls for immunohistochemistry included the omission of the pri-
mary antibody or using normal mouse serum in place of the primary anti-
body. Controls for in situ hybridization included the application of an unre-
lated probe and a probe that is identical, instead of complementary, to the
sequence of the SARS genomic target. Aside from the controls that were
described above for the two techniques, additional controls were performed
for the double staining, including in situ hybridization and immunostaining
Table IV. Clinical data for 18 suspected SARS cases
Case 
no. Age/gender Course Clinical symptoms Chest radiograph Lymphopenia
SARS pathogen 
(real-time PCR) History
Steroid 
treatment Diagnosis
001 51/male 45 fever and cough infiltrates in the right 
lower portion of the lung
yes yes healthy   SARS
003 50/male 33 fever, cough, 
and shortness 
of breath 
bilateral ground-glass 
changes
yes yes coronary heart disease, 
primary hypertension
  SARS
005 31/male 35 fever and
nonproductive 
cough
ground-glass changes 
in periphery of left lower 
and right middle lobes
yes yes non-Hodgkin’s
lymphoma
  SARS
006 49/female 32 fever and
shortness 
of breath
interstitial infiltrates yes yes no notable 
medical history
  SARS
008 24/male 21 fever and cough bilateral patchy exudation 
in the lower lobes
yes yes psychosis   SARS
011 20/male 58 fever and cough bilateral patchy interstitial 
infiltrates in lower lobes
yes yes  healthy   SARS
015 58/male 62 fever, cough, 
and chest distress
bilateral patchy ill-defined 
air-space shadowing
yes yes chronic liver 
disease (hepatitis B), 
coronary heart disease
  SARS
018 52/female 16 fever and
nonproductive 
cough
infiltrates in the right 
lower portion of the lung
yes yes bronchopulmonary 
tuberculosis 
  SARS
002 38/male 1 fever unknown no no healthy   anaphylactic 
shock
004 40/male 35 unknown no no duodenal 
ampulla ulcer
  duodenal 
perforation
007 40/male – unknown - no unknown mechanical 
asphyxiation
009 91/male 8 fever and cough  hydrothorax 
in the left pectoral cavity
yes no chronic pulmonary 
tuberculosis, 
emphysema
  bronchopneumonia, 
tuberculosis
010 30/male – fever and cough unknown no no healthy   suicide, hemorrhagic shock, 
interstitial pneumonia
013 87/male 4–5 h fever and cough, 
diarrhea
unknown yes no thrombosis 
in brain and logagnosia
  bronchopneumonia, 
emphysema
014 36/male 1 fever and headache bilateral patchy interstitial 
infiltrates in lower lobes
yes no healthy   lobular 
pneumonia
016 28/male 10 fever and cough infiltrates in the right lower 
and left middle 
portion of the lung
yes no healthy   fibrinous hemorrhagic 
pneumonia
017 59/male 10 fever, cough, 
and shortness 
of breath
bilateral interstitial infiltrate 
with reticulonodular pattern
yes no healthy   confluent 
bronchopneumonia
019 43/female 2 fever and diarrhea bilateral focal 
consolidation of the lung
yes no anemia   confluent bronchopneumonia, 
serous-fibrinous pericarditisJEM VOL. 202, August 1, 2005 423
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alone, to ensure that one reaction did not interfere, diminish, or enhance
the reaction of the other.
Because the pathology of the autopsy cases represents the mid and the
late stages of the disease, the peripheral blood samples were taken from 22
patients who had confirmed SARS at 3 to 16 d after the onset of high fever
to study relatively early changes. Blood samples from 4 patients who did not
have SARS were examined as controls. 100 white blood cells per patient
were examined with a transmission electron microscope (Jeol - JEM-
100CX II) operating at 100 kW.
In addition, the lymphocyte counts from 65 patients who had con-
firmed SARS—50 of whom were treated with steroids (glucocorticoid 30
 g/kg) and the other 15 were not treated—and 35 patients who had misdi-
agnosed cases—20 of whom were treated with steroids and the other 15
were not treated—were analyzed retrospectively. The identification of con-
firmed and misdiagnosed cases was achieved by the SARS antibody test de-
scribed above.
The study was approved by the Institutional Scientific and Ethics
Committee of the Health Science Center, Peking University.
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